Pfizer Inc. (NYSE:PFE) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 277,985 shares of the biopharmaceutical company’s stock after selling 28,265 shares during the period. Fiduciary Trust Co’s holdings in Pfizer were worth $7,375,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter worth $28,000. Finally, Noble Wealth Management PBC bought a new stake in Pfizer in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Down 3.0 %

PFE opened at $22.28 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $126.36 billion, a PE ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. The stock’s fifty day moving average is $24.02 and its 200-day moving average is $25.56. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.72%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.